dehydroepiandrosterone sulfate and orteronel

dehydroepiandrosterone sulfate has been researched along with orteronel in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Agus, DB; Bargfrede, M; Carthon, B; Clark, WR; Gandhi, JG; Heath, E; Kong, N; Lin, J; Liu, G; Moran, S; Oh, WK; Petrylak, DP; Suri, A	1

Trials

1 trial(s) available for dehydroepiandrosterone sulfate and orteronel

Article	Year
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. Investigational new drugs, 2015, Volume: 33, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dehydroepiandrosterone Sulfate; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Male; Middle Aged; Naphthalenes; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Taxoids; Testosterone	2015

Article

Year

Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.

Investigational new drugs, 2015, Volume: 33, Issue:2

Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dehydroepiandrosterone Sulfate; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Male; Middle Aged; Naphthalenes; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Taxoids; Testosterone

2015